Drugs / OCA 5 mg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01933503 | Oct → Nov 2013 | — | Intercept Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCA 5 mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01933503 ↗ |
| Action | Activate | “a bile acid analogue and farnesoid X receptor agonist” PMID 30144429 ↗ Aug 2018 |
| Modality | Small molecule | “Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases.” PMID 27743502 ↗ Oct 2016 |
| Route | Oral | “OCA 5 mg by mouth for 14 days” NCT01933503 ↗ |